HomeCLLS • NASDAQ
add
Cellectis SA
Previous close
$3.03
Day range
$2.87 - $3.00
Year range
$0.96 - $3.77
Market cap
206.29M USD
Avg Volume
68.44K
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 1.99M | -88.51% |
Operating expense | 30.90M | 37.94% |
Net income | -42.86M | -59.86% |
Net profit margin | -2.15K | -1,291.48% |
Earnings per share | -0.57 | 3.39% |
EBITDA | -26.42M | -960.84% |
Effective tax rate | -0.01% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 136.71M | 52.25% |
Total assets | 334.27M | 27.97% |
Total liabilities | 249.58M | 84.49% |
Total equity | 84.70M | — |
Shares outstanding | 71.75M | — |
Price to book | 2.57 | — |
Return on assets | -26.73% | — |
Return on capital | -44.33% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -42.86M | -59.86% |
Cash from operations | 39.72M | 3,355.49% |
Cash from investing | -13.65M | -8,275.46% |
Cash from financing | 41.58M | 924.67% |
Net change in cash | 69.35M | 1,664.40% |
Free cash flow | 33.89M | 252.26% |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
235
